The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world’s most dangerous bacteria.
“The persistent failure to develop, manufacture, and distribute effective new antibiotics is further fueling the impact of antimicrobial resistance (AMR) and threatens our ability to successfully treat bacterial infections,” says Dr. Hanan Balkhy, WHO Assistant Director General on AMR.
Almost all the new antibiotics that have been brought to market in recent decades are variations of antibiotic drugs classes that had been discovered by the 1980s.
(BOSTON/LONDON) – Leading funders of research and development of new antibiotics and other products targeting antibiotic-resistant bacteria, often called ‘superbugs’, have just released a document providing comprehensive guidance on strategies and activities to support Stewardship and Access for companies bringing new antibacterial products to market.
The Stewardship and Access Plan Development Guide provides companies with a framework to develop plans so that their product will be used responsibly, minimizing the spread of antibiotic-resistant bacteria while helping patients get access to life-saving products.
The Tripartite AMR Country Self-Assessment Survey (TrACSS) helps to monitor country progress on the
implementation of AMR national actions plans and has been administered on an annual basis by the Tripartite organizations (Food and Agriculture Organization of the United Nations (FAO), World Organisation for Animal Health (OIE) and World Health Organization (WHO)) since 2016.
This report analyzes the global responses on the fourth round of TrACSS (2019-2020) and examines the global trends and actions towards addressing AMR in all sectors.
Complete country and global responses to all rounds of the survey can be accessed through the TrACSS database:
Click Link: Report
This report examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them even for viral infections, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Since the first State of the World’s Antibiotics report in 2015, antimicrobial resistance has leveled off in some high-income countries but continues to rise in many low- and middle-income countries (LMICs), where access to antibiotics has risen with increases in gross domestic product per capita. Per capita antibiotic consumption in LMICs is lower than in high-income countries, despite a higher infectious disease burden; however, consumption rates are rapidly converging. These trends reflect both better access to antibiotics for those who need them and increases in inappropriate antibiotic use.
Researchers at CDDEP have released, The State of the World’s Antibiotics in 2021, which presents extensive data on global antimicrobial use and resistance as well as drivers and correlates of antimicrobial resistance, based on CDDEP’s extensive research and data collection through ResistanceMap (www.resistancemap.org), a global repository that has been widely used by researchers, policymakers, and the media.
Click Link: https://cddep.org/blog/posts/the-state-of-the-worlds-antibiotics-report-in-2021/#:~:text=Researchers%20at%20CDDEP%20have%20released,www.resistancemap.org)%2C
The new INEOS Oxford Institute for Antimicrobial Resistance is established at the birthplace of penicillin development. Resistance to existing antibiotics is arguably the world’s greatest healthcare challenge, known as the ‘silent pandemic’. The donation by INEOS is one of the largest ever to a UK university and creates a new model of partnership to tackle this urgent global issue. Researchers will seek to develop new drugs for animals and humans, as well as promote more responsible use of the antibiotics we have. Lord Jim O’Neill said, “This new institute could be the breakthrough moment the global AMR challenge needs”.
Click Link: INEOS AMR
Europe’s first AMR Patient Group was officially launched on the 18th November 2020 to coincide with European Antibiotic Awareness Day 2020 and World Antimicrobial Awareness Week (18-24 November). The AMR Patient Group is an initiative by Health First Europe and is comprised of national patient associations from across Europe. The group aims to address the gap in awareness at the patient-level about the danger of antibiotic misuse and the lack of effective infection prevention measures. The AMR Patient Group will empower patients across Europe with the necessary knowledge about antimicrobial resistance so that everyone understands when it is appropriate to take antibiotics and how to take them responsibly.
The key objectives of the AMR Patient Group are:
1. Raising patient awareness about AMR and HAIs to help reduce antibiotic misuse.
2. Building a consistent patient voice across Europe to advocate for national policies to tackle AMR and HAIs.
3. Broadening the AMR debate to include infection prevention and control measures.
Click link: AMR Patient Group
Rates of increase of antibiotic resistance and ambient temperature in Europe: a cross-national analysis of 28 countries between 2000 and 2016
Just published in Eurosurveillance – Europe’s journal on infectious disease surveillance, epidemiology, prevention and control
Click link below for details
Jointly organised by the BSAC and GARDP. For 2021, the conference collaborators are the Helmholtz Institute for Pharmaceutical Sciences (HIPS), the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network)
Free to Register. Click link below for Full Programme and Registration
Link for ACC2021
This report presents the results of the first multi-country and multi-professional study on the knowledge, attitudes and behaviours of healthcare workers regarding antibiotics, antibiotic use and antibiotic resistance across 30 European Union (EU) and European Economic Area (EEA) countries. While several studies have assessed the knowledge, attitudes and behaviours of the general public, healthcare students and individual professional groups in EU Member States, there is a lack of literature on the topic which considers the full breadth of healthcare workers.